Clinical trials: Pancreatic Metastasis
Pancreatic Cancer Metastatic
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
The purpose of this research study is to determine if the study drug, dasatinib, given in combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against metastatic pancreatic cancer.
- Trial name
- FOLFOX-D (NCT01652976)
- Testing
- Dasatinib, mFOLFOX6
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Florida
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Solid Organ Cancers
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells.
- Trial name
- NCT02714374
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Andrew Lowy
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Pancreas Cancer
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients.
- Trial name
- NCT00300950
- Testing
- GI-4000, Gemcitabine
- Where
- 28 sites in United States, India
- Volunteers
- 176 people
- Sponsor
- GlobeImmune
Recurrent Melanoma, Recurrent Pancreatic Cancer
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of small interfering ribonucleic acid (siRNA)-transfected peripheral blood mononuclear cells APN401 (APN401) in treating patients with melanoma, kidney, or pancreatic…
- Conditions
- Recurrent Melanoma, Recurrent Pancreatic Cancer, Recurrent Renal Cell Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT02166255
- Testing
- siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
- Trial name
- NCT07189195
- Testing
- TR-002
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of California, Davis
Pancreas Neoplasms, Lymphatic Metastasis
Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion
The purpose of this study is to compare the diagnosis accuracy of FNA and FNB biopsy on pancreatic, retroperitoneal, mediastinum and pelvic cavity solid occupying lesions.
- Conditions
- Pancreas Neoplasms, Lymphatic Metastasis, Neoplasm Metastases, Unknown Primary Neoplasm Metastasis
- Trial name
- NCT02327065
- Testing
- EUS-FNA (EchoTip Ultra), EUS-FNB (EchoTip ProCore)
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Huazhong University of Science and Technology
Metastatic Pancreatic Cancer
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy
This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan.
- Trial name
- NCT07122466
- Testing
- Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwell Health
Advanced Pancreatic Cancer
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04239001
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Pancreatic Tumor, Periampullary Carcinoma Resectable
Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors
This multicentre, prospective and randomized study aims(1:1) to compare the rate of recurrence, metastasis and survival according to the levels of intraoperative circulating tumor cells (CTCs) during cephalic…
- Conditions
- Pancreatic Tumor, Periampullary Carcinoma Resectable, Circulating Tumor Cells, Metastasis
- Trial name
- CETUPANC (NCT03340844)
- Testing
- No Touch (NT), Superior Mesenteric Artery First (SMA)
- Where
- Spain
- Volunteers
- 86 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy.
- Trial name
- LAPTOP (NCT04247165)
- Testing
- Gemcitabine, Nab-paclitaxel, Nivolumab
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Herlev Hospital
Metastatic Pancreatic Cancer
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
This study is designed to determine the duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration.
- Trial name
- NCT00726037
- Testing
- Ontak
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Loyola University
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell
Safety Study of SEA-CD40 in Cancer Patients
This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma
- Trial name
- NCT02376699
- Testing
- Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40
- Where
- 19 sites in United States
- Volunteers
- 159 people
- Sponsor
- Seagen Inc.
Pancreatic Adenocarcinoma Metastatic
Scheduling Nab-paclitaxel With Gemcitabine
Metastatic pancreatic cancer is difficult to treat. Until recently, most patients would be offered treatment with a chemotherapy drug called gemcitabine.
- Trial name
- SIEGE (NCT03529175)
- Testing
- Abraxane (nab-paclitaxel), Gemcitabine
- Where
- 23 sites in United Kingdom
- Volunteers
- 146 people
- Sponsor
- CCTU- Cancer Theme
Biliary Tract Cancer, Colorectal Carcinoma
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
The investigational product used in this study, UCLH801 cells, is a CAR-T cell therapy specifically targeting CDH17. The proposed indication includes CDH17-positive advanced solid tumors, such as but not limited to colorectal…
- Conditions
- Biliary Tract Cancer, Colorectal Carcinoma, Gastric Cancer, Metastatic, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
- Trial name
- NCT06937567
- Testing
- CDH17 CAR-T, FAST LACO-Stim CDH17 CAR-T
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal…
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
- Trial name
- ASPIRE (NCT05254171)
- Testing
- SBP-101, Nab-paclitaxel, Gemcitabine
- Where
- 93 sites in United States, Australia and 8 more
- Volunteers
- 600 people
- Sponsor
- Panbela Therapeutics, Inc.
Solid Tumor, Advanced Cancer
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05076760
- Testing
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memgen, Inc.
Breast Cancer, Colorectal Cancer
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT00709462
- Testing
- CDX1307
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celldex Therapeutics
Pancreas Cancer, Metastatic Pancreatic Cancer
FOLFIRINOX + NIS793 in Pancreatic Cancer
This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and…
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT05417386
- Testing
- FOLFIRINOX, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Colin D. Weekes, M.D., PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.